Evidence map›Paper›PMID 30657054›Full record

ArticleMicrobial cell factories2019

Engineering the flagellar type III secretion system: improving capacity for secretion of recombinant protein.

Charlotte A Green, Nitin S Kamble, Elizabeth K Court, Owain J Bryant, Matthew G Hicks, Christopher Lennon, Gillian M Fraser, Phillip C Wright, Graham P Stafford

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Microbial medicines: Unlocking the therapeutic potential of the microbiome in cancer treatment.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Review
  5. Article
  6. Vitamin D3 contribution to systemic and local control ofFrontiers in molecular biosciences · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Highly Expressed Soluble Recombinant Anti-GFP VHHs inFrontiers in molecular biosciences · 2022
    Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Charlotte A GreenIntegrated BioSciences, School of Clinical Dentistry, University of Sheffield, Sheffield, S10 2TA, UK.
Nitin S KambleIntegrated BioSciences, School of Clinical Dentistry, University of Sheffield, Sheffield, S10 2TA, UK.
Elizabeth K CourtIntegrated BioSciences, School of Clinical Dentistry, University of Sheffield, Sheffield, S10 2TA, UK.
Owain J BryantDepartment of Pathology, University of Cambridge, Cambridge, CB2 1QP, UK.
Matthew G HicksIntegrated BioSciences, School of Clinical Dentistry, University of Sheffield, Sheffield, S10 2TA, UK.
Christopher LennonFUJIFILM Diosynth Biotechnologies, Belasis Avenue, Stockton-on-Tees, Billingham, TS23 1LH, UK.
Gillian M FraserDepartment of Pathology, University of Cambridge, Cambridge, CB2 1QP, UK.
Phillip C WrightSchool of Engineering, The Faculty of Science, Agriculture and Engineering, Newcastle University, Newcastle, NE1 7RU, UK.
Graham P StaffordIntegrated BioSciences, School of Clinical Dentistry, University of Sheffield, Sheffield, S10 2TA, UK. g.stafford@sheffield.ac.uk.ORCID http://orcid.org/0000-0002-9078-8254
University of Sheffield · GBUniversity of Cambridge · GBFujifilm (United Kingdom) · GBNewcastle University · GBUniversity of Nottingham · GB

Funding

Biotechnology and Biological Sciences Research Council BB/F018681/1Biotechnology and Biological Sciences Research Council BB/J016322/1Biotechnology and Biological Sciences Research Council BB/M007197/1Biotechnology and Biological Sciences Research Council CBMNet Business Innovation VoucherDepartment of Pathology, University of Cambridge John Lucas Walker studentship
6 · The paper itself

Abstract

backgroundMany valuable biopharmaceutical and biotechnological proteins have been produced in Escherichia coli, however these proteins are almost exclusively localised in the cytoplasm or periplasm. This presents challenges for purification, i.e. the removal of contaminating cellular constituents. One solution is secretion directly into the surrounding media, which we achieved via the 'hijack' of the flagellar type III secretion system (FT3SS). Ordinarily flagellar subunits are exported through the centre of the growing flagellum, before assembly at the tip. However, we exploit the fact that in the absence of certain flagellar components (e.g. cap proteins), monomeric flagellar proteins are secreted into the supernatant.

resultsWe report the creation and iterative improvement of an E. coli strain, by means of a modified FT3SS and a modular plasmid system, for secretion of exemplar proteins. We show that removal of the flagellin and HAP proteins (FliC and FlgKL) resulted in an optimal prototype. We next developed a high-throughput enzymatic secretion assay based on cutinase. This indicated that removal of the flagellar motor proteins, motAB (to reduce metabolic burden) and protein degradation machinery, clpX (to boost FT3SS levels intracellularly), result in high capacity secretion. We also show that a secretion construct comprising the 5'UTR and first 47 amino acidsof FliC from E. coli (but no 3'UTR) achieved the highest levels of secretion. Upon combination, we show a 24-fold improvement in secretion of a heterologous (cutinase) enzyme over the original strain. This improved strain could export a range of pharmaceutically relevant heterologous proteins [hGH, TrxA, ScFv (CH

conclusionsWe have engineered an E. coli which secretes a range of recombinant proteins, through the FT3SS, to the extracellular media. With further developments, including cell culture process strategies, we envision further improvement to the secreted titre of recombinant protein, with the potential application for protein production for biotechnological purposes.

Indexed as

Metabolic Engineering5' Untranslated RegionsCarboxylic Ester HydrolasesEscherichia coliEscherichia coli ProteinsFlagellaFlagellinHuman Growth HormoneHumansRecombinant ProteinsThioredoxinsType III Secretion Systems5' Untranslated RegionsCarboxylic Ester HydrolasescutinaseEscherichia coli ProteinsFlagellinFliC protein, E coliHuman Growth HormoneRecombinant ProteinsThioredoxinsType III Secretion SystemsBiotechnologyFlagellarRecombinant protein secretionSecretion assayStrain engineeringSynthetic biology

Identifiers

PMID30657054
PMCPMC6337784
OpenAlexW2910784510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.